Food and Drug Administration

Regulations Requiring Manufacturers To Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients Gao ID: OGC-99-22 December 21, 1998

Pursuant to a legislative requirement, GAO reviewed the Food and Drug Administration's (FDA) new rule on requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. GAO noted that: (1) the final rule would require pediatric studies of certain new and marketed drugs and biological products; (2) it would also partially address the lack of pediatric use information by requiring that manufacturers of certain products provide sufficient data and information to support directions for pediatric use for the claimed indications; and (3) FDA complied with applicable requirements in promulgating the rule.



The Justia Government Accountability Office site republishes public reports retrieved from the U.S. GAO These reports should not be considered official, and do not necessarily reflect the views of Justia.